Amid Boom Days for Biotech, Inhibrx Lines Up Another IPO Effort

On July 29, 2020 Inhibrx reported that it has set a preliminary $100 million IPO goal, up by about one-third from the target it set last year. The company has applied for a Nasdaq listing under the stock symbol "INBX (Press release, Inhibrx, JUL 29, 2020, View Source [SID1234562541])."

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

As of late June, every biotech IPO this year had priced at or above the midpoint of its price range or offered more shares than it initially planned, according to research firm Renaissance Capital.

Inhibrx has four investigational drugs all in Phase 1 testing; three for cancers and another for a rare genetic disease called alpha-1 antitrypsin (AAT) deficiency. The drug candidates deploy single-domain antibodies, antibody fragments that the company believes may best other antibody and biologic therapies on safety and efficacy because of their smaller size and "highly modular" properties.

The company’s most advanced candidate, INBRX-109, is under evaluation in patients with chondrosarcoma and mesothelioma, two rare and aggressive cancers. The drug is designed to stimulate DR5, a member of the tumor necrosis factor (TNF) receptor superfamily, which plays a role in immune response.

Also in early testing is INBRX-106, which is intended to stimulate OX40, another TNF receptor superfamily member, in locally advanced or metastatic solid tumors, and INBRX‑105, which is designed to both inhibit the protein PD-L1 and to stimulate 4-1BB, a receptor found on T cells, to enhance the anti-tumor immune response. Based on preclinical data, Inhibrx says that both drug candidates could be used to complement or replace the use of a class of approved cancer immunotherapies called checkpoint inhibitors.

A Phase 1 study for its AAT program was paused due to the COVID-19 pandemic, but the company aims to resume enrollment in the fourth quarter. Italy’s Chiesi Group last year acquired the option to exclusively license global rights to the AAT program, excluding the US and Canada.

The company anticipates reporting initial data from INBRX-109 and INBRX-106 by year’s end, and additional data from all four programs during 2021.

With its IPO cash the company plans to advance these potential treatments through the ongoing trials and to scale up its commercial manufacturing activities. Currently the biotech’s largest outside shareholders are Lilly Asia Ventures, which owns nearly 10 percent of the company and RA Capital, which holds 8.4 percent, according to the IPO paperwork.

Since raising $40 million last year from Viking Global Investors in the form of a convertible note, Inhibrx has raised $15 million more in a similar financing, from Viking and other investors, according to its prospectus.

The company was founded in 2010 by Mark Lappe, Brendan Eckelman, and Quinn Deveraux, the company’s CEO, chief scientific officer, and head of early research, respectively.

Pancreatic Cancer Action Network and GeneCentric Therapeutics Launch Partnership in Pancreatic Cancer Research

On July 29, 2020 The Pancreatic Cancer Action Network (PanCAN) and GeneCentric Therapeutics, Inc. reported that they have entered into a collaborative research partnership for the advancement of RNA-based molecular signatures for pancreatic cancer disease progression and drug response (Press release, GeneCentric Therapeutics, JUL 29, 2020, View Source [SID1234564814]). The collaboration will combine GeneCentric’s single patient RNA-based report, including its Pancreatic Cancer Subtype Profiler (PurIST) for subtyping pancreatic ductal adenocarcinoma tumors (PDAC), with PanCAN’s extensive collection of patient molecular and outcomes data generated through its scientific and clinical programs.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"GeneCentric is advancing promising molecular signatures of disease progression and drug response in pancreatic cancer based on tumor subtyping through next generation RNA sequencing of the tumor and tumor/immune microenvironment, and immunogenomics," said Dr. Lynn Matrisian, Chief Science Officer of PanCAN. "The collaboration, which will involve profiling and data analyses from our Know Your Tumor program and Precision PromiseSM adaptive clinical trial, is designed to advance our goals of improving treatment responses and survival of PDAC patients, accelerating the development of novel therapies and defining potential curative strategies for people diagnosed with this devastating disease."

"PanCAN, with its leading-edge, innovative research programs to accelerate new therapies to the clinic and dramatically improve treatment options for pancreatic cancer patients, is an ideal partner for GeneCentric," said Dr. Mike Milburn, President and CEO of GeneCentric. "We are honored to work with the PanCAN team and their renowned collaborators to advance and apply novel molecular signatures to support landmark initiatives such as the Precision Promise study as well as other pivotal research in the pursuit of cures for patients."

The collaboration will involve two research projects and is focused on GeneCentric’s single patient molecular report, including two PurIST defined PDAC subtypes, Basal (gemcitabine/nab-paclitaxel responsive) and Classical (FOLFRINOX responsive). One study, aimed at the molecular characterization of potential treatment response, will be a retrospective analysis of patient data from the Know Your Tumor Program at diagnosis and treatment outcome. The second initiative is in conjunction with PanCAN’s Precision PromiseSM clinical trial to assess molecular signatures of patients at enrollment and association with treatment responses. The three-year study will enable application of the range of GeneCentric’s current PDAC as well as pan-cancer tumor and immunogenomic signatures of treatment response, as well as exploration of novel PDAC-related signatures.

Entry into a Material Definitive Agreement

On July 29, 2020, Milestone Pharmaceuticals Inc. (the "Company") reported that entered into an Open Market Sale AgreementSM (the "Agreement") with Jefferies LLC, as sales agent ("Jefferies" or the "Agent"), under which the Company may issue and sell its common shares, no par value per share (the "Common Shares"), from time to time for an aggregate sales price of up to $50,000,000 through Jefferies as its sales agent (Press release, Milestone Pharmaceuticals, JUL 29, 2020, View Source [SID1234562482]). The Common Shares to be sold under the Agreement, if any, will be offered and sold pursuant to the Company’s shelf registration statement on Form S-3 (File No. 333-239318), which was declared effective by the Securities and Exchange Commission on July 6, 2020.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Company is not obligated to make any sales of Common Shares under the Agreement. Jefferies may sell the Common Shares by any method that is deemed to be an "at the market offering" as defined in Rule 415 of the Securities Act of 1933, as amended, including, without limitation, sales made directly on The Nasdaq Global Select Market or any other existing trading market for the Common Shares. Jefferies will use commercially reasonable efforts to sell the Common Shares under the Agreement from time to time, based upon instructions from the Company (including any price, time or size limits or other customary parameters or conditions the Company may impose). The Company will pay Jefferies a commission equal to 3.0 percent (3.0%) of the aggregate gross sales proceeds of any Common Shares sold through Jefferies under the Agreement (or as otherwise agreed between the Company and the Agent with respect to any Common Shares sold under the Agreement), and also has provided Jefferies with customary indemnification and contribution rights. In addition, the Company has agreed to reimburse certain legal expenses and fees incurred by Jefferies in connection with the offering up to a maximum of $65,000.

The offering of Common Shares pursuant to the Agreement will terminate upon the earlier of (i) the sale of all Common Shares subject to the Agreement or (ii) termination of the Agreement in accordance with its terms.

The foregoing description of the Agreement is not complete and is qualified in its entirety by reference to the full text of the Agreement, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference. The legal opinion of Osler, Hoskin & Harcourt LLP relating to the Common Shares being offered pursuant to the Agreement is filed as Exhibit 5.1 to this Current Report on Form 8-K.

This Current Report on Form 8-K shall not constitute an offer to sell or the solicitation of an offer to buy the Common Shares nor shall there be any offer, solicitation or sale of the Common Shares in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

Scientists using AI to benefit cancer patients

On July 29, 2020 Case Western Reserve University scientists reported are developing artificial intelligence (AI) tools to help surgeons and oncologists identify the subtle but critical differences between a recurring tumor and damaged non-cancerous tissue on post-operative MRI scans of certain cancer patients (Press release, Case Western Reserve University, JUL 29, 2020, View Source [SID1234562508]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The work is being led by Pallavi Tiwari, PhD, and Satish Viswanath, PhD. Both are faculty members in the Case Western Reserve School of Medicine and lead researchers in the Center for Computational Imaging and Personal Diagnostics (CCIPD) at the Case School of Engineering.

Tiwari, Viswanath and several collaborators were recently awarded a $1.15 million grant from the National Cancer Institute (NCI)’s Informatics Technology in Cancer Research (ITCR) program to pursue development and dissemination of the AI-informed tools.

Avoiding second surgeries

The potential benefit for doctors and their patients: Fewer unnecessary surgeries to remove suspect tissue which now can only be confirmed to be non-cancerous after initial therapy.

Doctors often end up performing those surgeries for one simple reason: Tissue that has been scarred and damaged—even killed—by chemotherapy or radiation resembles a recurring tumor on an MRI scan, the researchers said.

"They look very similar on the image, at least from what the human eye can perceive," said Viswanath, who specializes in colorectal cancers, while Tiwari focuses on brain cancers.

For a colorectal cancer patient, that can often mean getting a proctectomy (a portion of the rectum removed), a radical procedure that significantly reduces quality of life, Viswanath said.

"So, until now, if you don’t take the lesion out, you can’t tell if it’s a tumor," Tiwari said. "But you really don’t want to keep hitting cancer patients with unnecessary surgeries—and that’s especially true in both brain and colorectal cancers."

Their proposed tool would harness the interpretive power of the center’s deep-learning computers, which will use the AI tools being designed and developed in this project to tease out miniscule variations between the tumors and damaged tissue on MRI scans.

Those previously unseen variations differentiate tumors from dead tissue (known as necrosis, when most or even all of the cells in the tissue have died) or severely damaged scar tissue (known as fibrosis).

The research covers brain and colorectal cancer because they are similar in "terms of over-treatment," Viswanath said, referring to decisions by some surgeons to not risk a second surgery when it is actually necessary, or the earlier example of an unnecessary surgery.

Spreading the word

The NCI grant also calls for the researchers to begin making the tool available to other scientists, with an eye on future dissemination among clinicians.

"Dissemination of this information is a key to this grant," Tiwari said. "The research community is starting to appreciate the importance of radiomics, and there is a lot of excitement. Hopefully, the next step is to really get this into the clinical community as well."

Radiomics refers to the method of extracting certain features from radiographic medical images using data-characterization algorithms. These features, when interpreted by the computer, could uncover disease characteristics that fail to be appreciated by the naked eye.

Other collaborators on the project include neuro-oncologist Manmeet Ahluwalia, MD (Cleveland Clinic); colorectal surgeon Sharon Stein, MD, (University Hospitals); imaging scientist Nicole Seiberlich, PhD (University of Michigan); Andrew Janowczyk (Research Faculty, CCIPD); and Anant Madabhushi, the F. Alex Nason Professor II of Biomedical Engineering at Case Western Reserve and director of the CCIPD.

This new work also meshes with previous projects under the auspices of the CCIPD and the Case Comprehensive Cancer Center at the School of Medicine, and will allow for the centers to better connect pathology and radiology, Madabhushi said.

"The CCIPD will now have three concurrent NCI/ITCR grants focusing on AI tools for cancer diagnosis and prognosis—two focused on AI in pathology," Madabhushi said. "Ultimately, that synergy will allow for more precise understanding and prognosis of cancer, in turn, leading to the betterment of the cancer patient."

Some of that work is referenced in academic research, said Viswanath, the corresponding author of a recently published paper in the journal Cancers.

McKesson Declares Quarterly Dividend July 29, 2020

On July 29, 2020 The Board of Directors of McKesson Corporation (NYSE:MCK) reported a regular dividend of 42 cents per share of common stock (Press release, McKesson, JUL 29, 2020, View Source [SID1234562525]). The dividend will be payable on October 1, 2020, to stockholders of record on September 1, 2020.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!